Research Reveals How Cancer Cells Resist Their Own Toxin

Josep Carreras Leukaemia Research Institute

Cancer cells must protect themselves from the harmful substances they produce as they grow. Now, researchers have identified how they neutralise one of these substances, formaldehyde, while keeping another defence against cell death intact. The findings suggest a way to attack both defences together, and the next step is to find out whether it could become a treatment.

Formaldehyde is produced naturally inside cells and can damage DNA by binding it to nearby proteins. Cells neutralise it using glutathione, a molecule that protects against chemical damage. Glutathione also prevents ferroptosis, a form of cell death caused by damage to fats in the cell membrane. Both tasks depend on the same supply of glutathione, so using it to deal with formaldehyde can leave less available for the other task. The study explains how cancer cells can maintain both defences.

The research, led by Lucas Pontel's group at the Josep Carreras Leukaemia Research Institute, focused on a protein called NRF2. Often overactive in tumours, NRF2 controls a process that helps cancer cells neutralise formaldehyde while preserving their glutathione supply.

How cancer cells preserve their defences

NRF2 increases production of SLC7A11, a protein that transports a molecule called cystine into cells. Once inside, cystine is converted into cysteine, which can react directly with formaldehyde without using glutathione. This reaction produces a stable compound called thioproline, which the researchers detected in cancer cells. By taking in more cystine, the cells can deal with formaldehyde and keep glutathione available to prevent ferroptosis.

Blocking both defences

Blocking SLC7A11 in cells exposed to high levels of formaldehyde stopped protein production and triggered cell death. The researchers also used drugs to block both cystine uptake and glutathione production. This combination killed leukaemia cells, as well as various types of solid tumours such as lung and colon cancers and brain tumour cells.

What this could mean for leukaemia

The results suggest that targeting both defences could be worth investigating as a treatment approach for leukaemia. In patients with myeloid leukaemia, higher levels of SLC7A11 are associated with poorer survival. This raises the possibility that these cancers depend on the defence system identified in the study. The team now plans to investigate whether blocking it could lead to a safe and effective treatment.

The study also involved Dr Gael Roué's group at the Josep Carreras Institute and researchers from the University of Leicester (United Kingdom), the Institute of Biomedicine of Buenos Aires (IBioBA-MPSP, Argentina) and the International University of Catalonia (UIC).

Work in Dr Lucas Pontel's laboratory was funded by the Spanish Ministry of Science, Innovation and Universities – State Research Agency (AEI), the Deutsche José Carreras Leukämie-Stiftung, the Departament de Recerca i Universitats (Generalitat de Catalunya) and the European Union's Horizon Europe Marie Skłodowska-Curie Actions programme (CarrerasLeaders).

Reference article: Agustín E. Morellato et al.,NRF2 coordinates cystine import and glutathione use to sustain ferroptosis resistance and formaldehyde tolerance in cancer. Sci.Adv.12,eaea1431(2026).DOI: 10.1126/sciadv.aea1431

About the Josep Carreras Leukaemia Research Institute

The Josep Carreras Leukaemia Research Institute is Spain's dedicated research institute for blood cancers, one of the very few free-standing institutes in the world focused exclusively on this disease space.

Founded in 2010, the Institute was recognized in 2024 as a Severo Ochoa Centre of Excellence by the Spanish Ministry of Science, Innovation and Universities. IJC is also a center of excellence CERCA of the Catalan Government and is embedded in a network of six affiliated hospitals across Catalonia. The Institute's researchers bring together expertise in epigenetics, immunology, stem cell biology, spatial transcriptomics, computational oncology, and clinical investigation, all directed at a single purpose: curing blood cancers.

The Institute's translational strategy is built around three interconnected pillars: the Catalonia Translational Working Groups, which unite clinicians, scientists, and diagnostics experts around the most urgent cross-disease challenges in hematological malignancy; PATH2CURE, a comprehensive therapeutics platform that advances discoveries from target identification through preclinical validation toward clinical application; and the Center for 22nd Century Diagnostics (C22D), a joint initiative with the Barcelona Supercomputing Center that integrates spatial biology, multi-omics, and artificial intelligence to generate dynamic, patient-specific diagnostic models capable of predicting how disease will evolve and resist. Together, these pillars form a continuous translational cycle connecting patient care, biological discovery, and clinical innovation. This is made possible thanks to the philanthropic mission of the Josep Carreras Leukaemia Foundation and by the commitment of every person at the Institute to the patients who cannot afford to wait.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.